DAMGO: Difference between revisions
Jump to navigation
Jump to search
m (Protected "DAMGO": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 23: | Line 23: | ||
{{CMG}} | {{CMG}} | ||
__NOTOC__ | __NOTOC__ | ||
==Overview== | ==Overview== | ||
| Line 32: | Line 32: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
{{Opioids}} | {{Opioids}} | ||
Latest revision as of 15:47, 4 September 2012
Template:Chembox new Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin) is a synthetic opioid peptide with high μ-opioid receptor specificity. It was synthesized as a biologically stable analog of δ-opioid receptor-preferring endogenous opioids, leu- and met-enkephalin.[1]
Its structure is H-Tyr-D-Ala-Gly-N-MePhe-Gly-OH.
References
- ↑ Handa BK, Land AC, Lord JA, Morgan BA, Rance MJ, Smith CF. "Analogues of β-LPH61–64 possessing selective agonist activity at μ-opiate receptors." European Journal of Pharmacology. 1981 Apr 9;70(4):531-40. PMID 6263640. doi:10.1016/0014-2999(81)90364-2